^
    Back
    Association details:
    Biomarker:ROS1 wild-type
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Cancer Med
    Title:

    First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial

    Published date:
    08/28/2023
    Excerpt:
    Patients with treatment-naïve stage IIIB/IV or recurrent nsNSCLC without driver mutations in ALK, EGFR, or ROS1, were randomized 1:1 to receive either nivolumab or placebo. Patients in both arms received paclitaxel, carboplatin, and bevacizumab, administered 3-weekly for a maximum of 6 cycles....Nivolumab plus platinum chemotherapy and bevacizumab demonstrated longer OS vs. the placebo combination.
    Secondary therapy:
    carboplatin + paclitaxel
    DOI:
    https://doi.org/10.1002/cam4.6348
    Trial ID:
    NCT03117049